Boris Gorsh

509 total citations
52 papers, 294 citations indexed

About

Boris Gorsh is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Boris Gorsh has authored 52 papers receiving a total of 294 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Hematology, 20 papers in Molecular Biology and 18 papers in Genetics. Recurrent topics in Boris Gorsh's work include Multiple Myeloma Research and Treatments (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Boris Gorsh is often cited by papers focused on Multiple Myeloma Research and Treatments (23 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (18 papers) and Chronic Myeloid Leukemia Treatments (13 papers). Boris Gorsh collaborates with scholars based in United States, United Kingdom and France. Boris Gorsh's co-authors include Vanja Sikirica, Patrick Lefèbvre, Marie‐Hélène Lafeuille, Arash Mostaghimi, Mei Sheng Duh, Samuel H. Zwillich, Jason Xenakis, Lynne Napatalung, Randall Winnette and Jie Zhang and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Boris Gorsh

46 papers receiving 290 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Boris Gorsh United States	8	103	73	66	58	57	52	294
Heidi Segers Belgium	14	91 0.9×	239 3.3×	126 1.9×	91 1.6×	12 0.2×	36	465
Wanda Knopińska‐Posłuszny Poland	9	112 1.1×	54 0.7×	93 1.4×	27 0.5×	18 0.3×	33	298
Alexandra Paravisini Spain	8	14 0.1×	27 0.4×	61 0.9×	20 0.3×	40 0.7×	15	349
Seung Won Choi South Korea	11	22 0.2×	33 0.5×	30 0.5×	64 1.1×	8 0.1×	40	373
Gianpaolo Marcacci Italy	8	80 0.8×	22 0.3×	115 1.7×	32 0.6×	22 0.4×	17	313
Fibo Ten Kate Netherlands	8	25 0.2×	46 0.6×	25 0.4×	25 0.4×	6 0.1×	11	307
Pankti Reid United States	12	30 0.3×	43 0.6×	233 3.5×	71 1.2×	11 0.2×	42	358
Nataliya Kuptsova‐Clarkson United States	9	30 0.3×	37 0.5×	61 0.9×	33 0.6×	36 0.6×	16	234
Natalie Pui Ha Chan Hong Kong	9	293 2.8×	103 1.4×	68 1.0×	39 0.7×	17 0.3×	21	475
Silvia Trappolini Italy	7	154 1.5×	39 0.5×	48 0.7×	23 0.4×	24 0.4×	13	290

Countries citing papers authored by Boris Gorsh

Since Specialization

Citations

This map shows the geographic impact of Boris Gorsh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Boris Gorsh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Boris Gorsh more than expected).

Fields of papers citing papers by Boris Gorsh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Boris Gorsh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Boris Gorsh. The network helps show where Boris Gorsh may publish in the future.

Co-authorship network of co-authors of Boris Gorsh

This figure shows the co-authorship network connecting the top 25 collaborators of Boris Gorsh. A scholar is included among the top collaborators of Boris Gorsh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Boris Gorsh. Boris Gorsh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sankar, K. Nathan, et al.. (2025). Real-World Treatment Patterns and Clinical Outcomes in Patients With Extensive-Stage Small Cell Lung Cancer Treated With First-Line Platinum-Based Chemotherapy and ≥ 2 Subsequent Lines of Therapy in the United States. Advances in Therapy. 43(1). 214–230.

Masárová, Lucia, Srđan Verstovšek, Francesca Palandri, et al.. (2025). Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosis. Future Oncology. 21(16). 2067–2075. 1 indexed citations

Daskalopoulou, Christina, Boris Gorsh, Samineh Deheshi, et al.. (2024). Myelofibrosis symptom assessment form total symptom score version 4.0: measurement properties from the MOMENTUM phase 3 study. Quality of Life Research. 34(3). 739–750.

Leleu, Xavier, et al.. (2023). Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database. European Journal Of Haematology. 111(1). 125–134. 7 indexed citations

Masárová, Lucia, Srđan Verstovšek, Sumati Rao, et al.. (2023). PB2183: TRANSFUSION-RELATED COST OFFSETS AND TIME BURDEN IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH MOMELOTINIB (MMB) VS DANAZOL (DAN). HemaSphere. 7(S3). e9317412–e9317412. 1 indexed citations

Mesa, Ruben A., Francesca Palandri, Srđan Verstovšek, et al.. (2023). PB2184: IMPACT OF TRANSFUSION BURDEN ON HEALTH-RELATED QUALITY OF LIFE AND FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS: POST HOC ANALYSIS OF SIMPLIFY-1 AND -2. HemaSphere. 7(S3). e3210233–e3210233. 1 indexed citations

Boytsov, Natalie, et al.. (2023). Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA. Supportive Care in Cancer. 31(6). 371–371. 3 indexed citations

Gupta, Vikas, Claire Harrison, Boris Gorsh, et al.. (2023). Red Blood Cell Transfusion Independence Status Is an Independent Predictor of Survival: A Post Hoc Time-Dependent Analysis of the Phase 3 Simplify-1, Simplify-2, and Momentum Trials. Blood. 142(Supplement 1). 3188–3188. 3 indexed citations

Boytsov, Natalie, et al.. (2023). HSD57 Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) on Second and Third Line (2L/3L) Therapy, Classified By Urbanicity and Ethnicity. Value in Health. 26(6). S248–S248. 1 indexed citations

10.

Masárová, Lucia, Srđan Verstovšek, Francesca Palandri, et al.. (2023). P1057: INDIRECT TREATMENT COMPARISONS OF MOMELOTINIB VS PACRITINIB SAFETY AND ANEMIA OUTCOMES IN PATIENTS WITH MYELOFIBROSIS. HemaSphere. 7(S3). e1863563–e1863563. 1 indexed citations

11.

Ailawadhi, Sikander, Rakesh Popat, David Kleinman, et al.. (2023). Treatment preferences of patients with relapsed or refractory multiple myeloma in the United States, United Kingdom, Italy, Germany, France, and Spain: results from a discrete choice experiment. Frontiers in Medicine. 10. 1271657–1271657. 9 indexed citations

12.

Regnault, Antoine, Boris Gorsh, Randy Davis, et al.. (2023). A toolbox of different approaches to analyze and present PRO-CTCAE data in oncology studies. JNCI Journal of the National Cancer Institute. 115(5). 586–596. 8 indexed citations

13.

Colin, Xavier, Will Sopwith, Shannon Ferrante, et al.. (2022). Assessing the treatment pattern, health care resource utilisation, and economic burden of multiple myeloma in France using the Système National des Données de Santé (SNDS) database: a retrospective cohort study. The European Journal of Health Economics. 24(3). 321–333. 5 indexed citations

14.

Mostaghimi, Arash, Lynne Napatalung, Vanja Sikirica, et al.. (2021). Patient Perspectives of the Social, Emotional and Functional Impact of Alopecia Areata: A Systematic Literature Review. Dermatology and Therapy. 11(3). 867–883. 56 indexed citations

15.

Gorsh, Boris, et al.. (2020). PCN309 Methodology for Evaluating Meaningful Change Thresholds in Patient-Reported Outcome (PRO) Measures for Corneal Events in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Receiving Single-Agent Belantamab Mafodotin (BELAMAF). Value in Health. 23. S477–S477. 2 indexed citations

16.

Benjamin, Katy, Ryan M. Murphy, Robyn von Maltzahn, et al.. (2020). Development of a conceptual model and patient-reported outcome measures for assessing symptoms and functioning in patients with heart failure. Quality of Life Research. 29(10). 2835–2848. 4 indexed citations

17.

Cooper, Lauren B., Steven Lippmann, Julia DiBello, et al.. (2019). The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. The American Journal of Cardiology. 124(4). 545–553. 26 indexed citations

18.

Lafeuille, Marie‐Hélène, et al.. (2012). Association Between Consistent Omalizumab Treatment and Asthma Control. The Journal of Allergy and Clinical Immunology In Practice. 1(1). 51–57. 23 indexed citations

19.

Lafeuille, Marie‐Hélène, et al.. (2012). Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Annals of Allergy Asthma & Immunology. 109(1). 59–64. 34 indexed citations

20.

Gorsh, Boris, et al.. (2011). PDB55 CLINICAL AND ECONOMIC EVALUATION OF A DIABETES MEDICATION MANAGEMENT PROGRAM: 2 YEAR PROGRAM UPDATE. Value in Health. 14(3). A101–A101. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact